3 Stocks Upping Dividends & 1 With A 10% Special Dividend Yield Several stocks are lifting their dividends, while one small pharma company just declared a special dividend that gives it a huge dividend yield. MarketBeat · Apr 16, 2025
3 Small-Cap Biotech Stocks With Game-Changing Potential The biotech industry offers a compelling investment opportunity due to its potential for disruptive innovations and high growth. Thus, investing in fundamentally strong small-cap stocks Esperion Therapeutics (ESPR), Innoviva, Inc. (INVA), and SIGA Technologies (SIGA) could be significantly rewarding. Read on…. StockNews.com · Oct 17, 2024
3 Small-Cap Healthcare Stocks With Breakthrough Potential The healthcare industry is growing massively owing to new drugs and technological innovations. Thus, investing in fundamentally robust small-cap stocks Theratechnologies (THTX), Anika Therapeutics. (ANIK), and SIGA Technologies (SIGA) could be a good idea. Read more to find out…. StockNews.com · Aug 15, 2024
WHO has declared mpox a global health emergency. What happens next? The World Health Organization (WHO) has declared mpox a public health emergency of international concern, after rising cases in the Democratic Republic of the Congo and the potential for further spread. The Conversation · Aug 15, 2024
3 Small-Cap Stocks With Big Potential Despite the associated risks, such as volatility, small-cap stocks with high-growth potential remain an attractive choice due to their outsized returns; thus, it could be prudent to consider adding strong stocks like Docebo (DCBO), SIGA Technologies (SIGA), and J.Jill (JILL) with big potential to capitalize on these industry trends. Keep… StockNews.com · Jun 14, 2024
3 Small-Cap Stocks With Big Potential May’s strong job report and a growing global economy might fuel the potential of small-cap stocks. Given this backdrop, it could be wise to buy Docebo (DCBO), SIGA Technologies (SIGA), and J.Jill (JILL), which have high growth potential. Keep reading…. StockNews.com · Jun 10, 2024
3 Biotech Stocks Under $20 Worth Watching in June The biotech industry’s long-term expansion is fueled by increasing medical needs globally, favorable government support, and technological advances. Given the industry’s rosy outlook, quality biotech stocks Equillium (EQ), SIGA Technologies (SIGA), and Shionogi & Co. (SGIOY) trading under $20 could be worth watching in June. Keep reading…. StockNews.com · May 31, 2024
3 Biotech Stocks to Consider Buying Right Away The biotechnology industry is thriving, fueled by solid government support, rising healthcare spending worldwide, gene editing breakthroughs, and rapid AI adoption. Hence, fundamentally solid biotech stocks Shionogi (SGIOY), United Therapeutics (UTHR), and SIGA Technologies (SIGA) could be ideal buys for potential gains. Keep reading…. StockNews.com · May 3, 2024
3 Biotech Stocks to Invest In Right Now for Long-Term Gains With the rapidly growing demand for personalized medicine, innovative solutions, and recent developments like AI in drug discovery, the biotech industry's prospects appear robust. Thus, quality biotech stocks Vertex Pharmaceuticals (VRTX), SIGA Technologies (SIGA), and Gilead Sciences (GILD) could be ideal candidates to buy now. Read more…. StockNews.com · Apr 12, 2024
2 Monkeypox Stocks to Watch This Week Increasing cases of monkeypox worldwide have led the WHO to declare it a global emergency. With the infection spread in more than 85 countries and governments rushing to curb the spread, vaccine manufacturers are poised to benefit significantly. Thus, we think monkeypox stocks Quest Diagnostics (DGX) and SIGA Technologies (SIGA)… StockNews.com · Aug 11, 2022
3 Active Stocks on Wall Street to Buy Right Now Even though the U.S. stocks ended July with decent gains, growing recession fears could keep the stock market under pressure in the near term. However, despite the current market headwinds, it could be wise to invest in fundamentally sound stocks, Microsoft (MSFT), SIGA Technologies (SIGA), and Fortinet (FTNT), which have… StockNews.com · Aug 5, 2022
Australia secures 450,000 new monkeypox vaccines. What are they and who can have them? Health Minister Mark Butler today announced Australia had secured 450,000 doses of a third-generation monkeypox vaccine, 22,000 of which will arrive later this week. The Conversation · Aug 4, 2022
Alternate monkeypox treatment caught in regulatory delays Alternate monkeypox treatment caught in regulatory delays Axios · Aug 4, 2022
Monkeypox Stocks On The Move: What Investors Should Know About The Outbreak The World Health Organization has declared the 2022 outbreak of monkeypox a global health emergency. The monkeypox crisis isn't as severe as the COVID-19 pandemic, but it has a number of health care and biotech stocks on the move. Benzinga · Aug 1, 2022
WEKU · Jul 30, 2022 Getting monkeypox treatment is easier, but still daunting and confusing Though doctors and advocates have helped speed up access to the antiviral pills – of which the U.S. has enough to treat 1.7 million people – health providers are few and forms are still required.
Benzinga · Jul 27, 2022 EXCLUSIVE: SIGA Technologies CEO Says Company Is Prepared To Respond To Monkeypox Outbreak With TPOXX Stockpile Upon Approval SIGA Technologies Inc (NASDAQ: SIGA) shares have rallied about 50% since the World Health Organization declared monkeypox a public health emergency of global concern.
Benzinga · Jul 13, 2022 The Daily Biotech Pulse: AstraZeneca's COVID-19 Vaccine As Effective As mRNA Shots, Humanigen's Lenzilumab Disappoints In COVID-19 Study, Positive Preclinical Data From Hoth's Alzheimer's Program Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · Jun 23, 2022 SIGA Technologies Announces $13M Worth Order For Its Monkeypox Treatment SIGA Technologies Inc (NASDAQ:SIGA) has announced approximately $13 million in procurement orders for oral TPOXX (tecovirimat) The order includes $11 million for initial procaurement from two new international jurisdictions and an approximate $2 million order from a country in the Asia Pacific region with an established contract for oral TPOXX. "We expect a…
Benzinga · May 25, 2022 Pharma Firm SIGA Cashes In On Monkeypox Scare New York-based pharmaceutical firm SIGA Technologies (NASDAQ: SIGA) is among the companies to benefit from the growing threat of monkeypox, recently pushing its shares to an almost decade-high after the company obtained approval in Europe to use its TPOXX antiviral drug for the treatment of monkeypox.
Benzinga · May 23, 2022 Why SIGA Technologies Stock Is Surging SIGA Technologies Inc (NASDAQ: SIGA) shares are trading higher Monday morning following increased social media interest amid elevated concerns surrounding a monkeypox outbreak.
Benzinga · May 19, 2022 Why SIGA Technologies Shares Are Trading Higher Today? The FDA approved the intravenous (IV) formulation of SIGA Technologies Inc's (NASDAQ:SIGA) TPOXX for smallpox. The oral formulation of TPOXX (tecovirimat) is approved in the US, Canada, and Europe to treat smallpox. The European approval also includes the treatment of monkeypox, cowpox, and complications from immunization with vaccinia. The IV formulation of TPOXX was…
StockNews.com · Apr 18, 2022 2 Top Stocks You Can Buy Now For Less Than $10 We believe fundamentally sound stocks, SIGA Technologies (SIGA) and Information Services Group (III), which are currently trading under $10, might be ideal investments now.